Novel inhaled respiratory medicine development pipeline

Pulmocide is generating a pipeline of novel, potent first-in-class anti-infective agents for delivery by inhaled administration for the treatment of life-threatening lower respiratory tract viral and fungal infections.

Why inhaled?

  1. Act quickly and precisely (cf systemic), lower-dose required
  2. Neutralize infection quickly, fewer (and less severe) unwanted effects
  3. Sustained action and minimal emergence of resistance
  4. Lower costs and better compliancepipeline june 2020